Development and validation of an ELISA method for detection of Growth Arrest Specific 6 (GAS6) protein in human plasma

Federica Alciato; Pier Paolo Sainaghi; Luigi Castello; Luca Bergamasco; Stefania Carnieletto; Gian Carlo Avanzi

doi:10.1080/15321810801888480

Development and validation of an ELISA method for detection of Growth Arrest Specific 6 (GAS6) protein in human plasma

Federica Alciato, Pier Paolo Sainaghi, Luigi Castello, Luca Bergamasco, Stefania Carnieletto, Gian Carlo Avanzi

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Gas6 protein is possibly involved in human diseases, but a validated plasma assay is lacking. So, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) method using commercially available reagents. An appropriate plasma-based matrix was prepared to optimize the assay. The ELISA method showed inter- and intra-assay coefficients of variation lower than 15%. Recoveries all fell within 15% of expected values. Plasma Gas6 concentration in 61 healthy donors was 20.3±3.8 ng/mL. Our assay meets FDA requirements for precision and accuracy for the validation of bioanalytical methods and it is suitable for research or diagnostic purposes.

Lingua originale	Inglese
pagine (da-a)	167-180
Numero di pagine	14
Rivista	Journal of Immunoassay and Immunochemistry
Volume	29
Numero di pubblicazione	2
DOI	https://doi.org/10.1080/15321810801888480
Stato di pubblicazione	Pubblicato - apr 2008

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1080/15321810801888480

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{734bdd7d01d64eed860444ec6d6f4c3f,

title = "Development and validation of an ELISA method for detection of Growth Arrest Specific 6 (GAS6) protein in human plasma",

abstract = "Gas6 protein is possibly involved in human diseases, but a validated plasma assay is lacking. So, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) method using commercially available reagents. An appropriate plasma-based matrix was prepared to optimize the assay. The ELISA method showed inter- and intra-assay coefficients of variation lower than 15%. Recoveries all fell within 15% of expected values. Plasma Gas6 concentration in 61 healthy donors was 20.3±3.8 ng/mL. Our assay meets FDA requirements for precision and accuracy for the validation of bioanalytical methods and it is suitable for research or diagnostic purposes.",

keywords = "Assay, Development, ELISA, Gas6, Normal concentration, Validation",

author = "Federica Alciato and Sainaghi, {Pier Paolo} and Luigi Castello and Luca Bergamasco and Stefania Carnieletto and Avanzi, {Gian Carlo}",

year = "2008",

month = apr,

doi = "10.1080/15321810801888480",

language = "English",

volume = "29",

pages = "167--180",

journal = "Journal of Immunoassay and Immunochemistry",

issn = "1532-1819",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Development and validation of an ELISA method for detection of Growth Arrest Specific 6 (GAS6) protein in human plasma

AU - Alciato, Federica

AU - Sainaghi, Pier Paolo

AU - Castello, Luigi

AU - Bergamasco, Luca

AU - Carnieletto, Stefania

AU - Avanzi, Gian Carlo

PY - 2008/4

Y1 - 2008/4

N2 - Gas6 protein is possibly involved in human diseases, but a validated plasma assay is lacking. So, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) method using commercially available reagents. An appropriate plasma-based matrix was prepared to optimize the assay. The ELISA method showed inter- and intra-assay coefficients of variation lower than 15%. Recoveries all fell within 15% of expected values. Plasma Gas6 concentration in 61 healthy donors was 20.3±3.8 ng/mL. Our assay meets FDA requirements for precision and accuracy for the validation of bioanalytical methods and it is suitable for research or diagnostic purposes.

AB - Gas6 protein is possibly involved in human diseases, but a validated plasma assay is lacking. So, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) method using commercially available reagents. An appropriate plasma-based matrix was prepared to optimize the assay. The ELISA method showed inter- and intra-assay coefficients of variation lower than 15%. Recoveries all fell within 15% of expected values. Plasma Gas6 concentration in 61 healthy donors was 20.3±3.8 ng/mL. Our assay meets FDA requirements for precision and accuracy for the validation of bioanalytical methods and it is suitable for research or diagnostic purposes.

KW - Assay

KW - Development

KW - ELISA

KW - Gas6

KW - Normal concentration

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=41149126693&partnerID=8YFLogxK

U2 - 10.1080/15321810801888480

DO - 10.1080/15321810801888480

M3 - Article

SN - 1532-1819

VL - 29

SP - 167

EP - 180

JO - Journal of Immunoassay and Immunochemistry

JF - Journal of Immunoassay and Immunochemistry

IS - 2

ER -

Development and validation of an ELISA method for detection of Growth Arrest Specific 6 (GAS6) protein in human plasma

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo